AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients ; volume:15 ; number:1 ; day:11 ; month:12 ; year:2024 ; pages:1-15 ; date:12.2024
Nature Communications ; 15, Heft 1 (11.12.2024), 1-15, 12.2024
- Creator
-
Knutson, Todd P.
Luo, Bin
Kobilka, Anna
Lyman, Jacqueline
Guo, Siyuan
Munro, Sarah A.
Li, Yingming
Heer, Rakesh
Gaughan, Luke
Morris, Michael J.
Beltran, Himisha
Ryan, Charles J.
Antonarakis, Emmanuel S.
Armstrong, Andrew J.
Halabi, Susan
Dehm, Scott M.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-024-54847-1
- URN
-
urn:nbn:de:101:1-2502222110151.081787190373
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Knutson, Todd P.
- Luo, Bin
- Kobilka, Anna
- Lyman, Jacqueline
- Guo, Siyuan
- Munro, Sarah A.
- Li, Yingming
- Heer, Rakesh
- Gaughan, Luke
- Morris, Michael J.
- Beltran, Himisha
- Ryan, Charles J.
- Antonarakis, Emmanuel S.
- Armstrong, Andrew J.
- Halabi, Susan
- Dehm, Scott M.
- SpringerLink (Online service)
Other Objects (12)
Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Ureter metastatic castration-resistant prostate cancer: a case report
Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Ureter metastatic castration-resistant prostate cancer: a case report
Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
Ureter metastatic castration-resistant prostate cancer: a case report
Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer